A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice

Medical Oncology

Volumn 31, Issue 1, 2014, Pages

  Barni, S ^a   Lorusso, V ^b   Giordano, M ^c   Sogno, G ^d   Gamucci, T ^e   Santoro, A ^f   Passalacqua, R ^g   Iaffaioli, V ^h   Zilembo, N ⁱ   Mencoboni, M ^j   Roselli, M ^k   Pappagallo, G ^l   Pronzato, P ^m  

^a TREVIGLIO HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c SANT ANNA HOSPITAL   (Italy)

^d IRCCS Istituto Giannina Gaslini   (Italy)

^e Oncology Department   (Italy)

^f HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^g CREMONA HOSPITAL   (Italy)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

^j VILLA SCASSI HOSPITAL   (Italy)

^k UNIVERSITY OF ROME TOR VERGATA   (Italy)

^l Azienda ULSS 13   (Italy)

^m UNIVERSITY OF GENOA   (Italy)

more..

Author keywords

G CSF; Guidelines; Italy; Observational study; Oncology practice; Solid tumors

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; COLORECTAL CANCER; DRUG DOSE REDUCTION; ENDOMETRIUM CANCER; EVIDENCE BASED PRACTICE; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CANCER; HUMAN; ITALY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; PROTOCOL COMPLIANCE; SARCOMA; SKIN CANCER; SOLID TUMOR; VERY ELDERLY; YOUNG ADULT; BLOOD; CLINICAL TRIAL; CYTOLOGY; LEUKOCYTE COUNT; METABOLISM; NEOPLASMS; NEUTROPHIL; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; GUIDELINE ADHERENCE; HUMANS; ITALY; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPHILS; PROSPECTIVE STUDIES; YOUNG ADULT;

MLCS; MLOWN;

EID: 84888786744     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0797-z     Document Type: Article

References (35)

1. Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258-66. (Pubitemid 43673249)
2. Pettengell R, Schwenkglenks M, Leonard R, et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer. 2008;16:1299-309.
3. Chirivella I, Bermejo B, Insa A, et al. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat. 2009;114:479-84.
4. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164-70.
5. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23:1178-84. (Pubitemid 46202274)
6. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25:3158-67. (Pubitemid 47218066)
7. Gatzemeier U, Kleisbauer JP, Drings P, et al. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study. Am J Clin Oncol. 2000;23:393-400. (Pubitemid 32429154)
8. Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol. 2010;28:2914-24.
9. von Minckwitz G, Kummel S, du Bois A, et al. Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/ cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol. 2008;19:292-8. (Pubitemid 351201710)
10. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21:1431-9. (Pubitemid 46594092)
11. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:626-33. (Pubitemid 38970553)
12. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42:2433-53. (Pubitemid 44442936)
13. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187-205. (Pubitemid 46638957)
14. Network NCC. National comprehensive cancer network clinical practice guidelines in oncology: myeloid growth factors. http://www.nccn.org/ professionals/physician-gls/PDF/myeloid-growth.pdf 2010; Version 1.2010.
15. http://www.aiom.it/default.asp. Associazione Italiana di Oncologica Medica.
16. Crawford J, Caserta C, Roila F. Hematopoietic growth factors: ESMO recommendations for the applications. Ann Oncol. 2009;20(Suppl 4):162-5.
17. ®) Summary of Product Characteristics. Amgen Ltd.
18. Lenograstim Summary of Product Characteristics. Chugai Pharma UK Ltd.
19. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993;29A:319-24. (Pubitemid 23025731)
20. Almenar D, Mayans J, Juan O, et al. Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain-results of the LEARN study. Eur J Cancer Care (Engl). 2009;18:280-6.
21. Weycker D, Hackett J, Edelsberg JS, et al. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother. 2006;40:402-7.
22. Morrison VA, Wong M, Hershman D, et al. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm. 2007;13:337-48. (Pubitemid 46958752)
23. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21:4524-31. (Pubitemid 46594022)
24. Papaldo P, Lopez M, Marolla P, et al. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol. 2005;23:6908-18.
25. von Minckwitz G, Schwenkglenks M, Skacel T, et al. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. Eur J Cancer. 2009;45:608-17.
26. Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol. 2000;18:2522-8. (Pubitemid 30432517)
27. Yang BB, Kido A, Shibata A. Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy. Pharmacotherapy. 2007;27:1387-93. (Pubitemid 47530445)
28. Holmes FA, Jones SE, O'Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol. 2002;13:903-9. (Pubitemid 34752686)
29. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20:727-31. (Pubitemid 34111380)
30. Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14:29-35. (Pubitemid 36150255)
31. Neulasta Summary of Product Characteristics. Amgen.
32. Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Cancer Netw. 2005;3:557-71. (Pubitemid 44265429)
33. Koumakis G, Vassilomanolakis M, Barbounis V, et al. Optimal timing (preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide. Oncology. 1999;56:28-35. (Pubitemid 29043893)
34. Crea F, Giovannetti E, Zinzani PL, Danesi R. Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization. Crit Rev Oncol Hematol. 2009;72:21-44.
35. Lyman G, Lalla A, Barron R, Dubois RW. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Curr Med Res Opin. 2009;25:401-11.